Could Apellis Pharmaceuticals, Inc. (APLS) Change Direction After Today’s Significant Increase?

March 14, 2018 - By Vivian Park

The stock of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is a huge mover today! The stock increased 12.63% or $2.83 during the last trading session, reaching $25.23. About 191,551 shares traded or 49.93% up from the average. Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) has 0.00% since March 14, 2017 and is . It has underperformed by 16.70% the S&P500.
The move comes after 8 months positive chart setup for the $1.27 billion company. It was reported on Mar, 14 by We have $26.24 PT which if reached, will make NASDAQ:APLS worth $50.80 million more.

More notable recent Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) news were published by: which released: “Apellis Pharmaceuticals to Present at the 36th Annual JP Morgan Healthcare …” on January 02, 2018, also with their article: “Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) to Ring The Nasdaq Stock Market …” published on December 13, 2017, published: “Apellis Pharmaceuticals Announces Pricing of Initial Public Offering” on November 09, 2017. More interesting news about Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) were released by: and their article: “Apellis Pharmaceuticals Announces 18-Month Results of Phase 2 Study (FILLY) of …” published on February 22, 2018 as well as‘s news article titled: “Apellis Pharmaceuticals: This Horse Is Lame” with publication date: January 09, 2018.

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The company has market cap of $1.27 billion. The Company’s lead product candidates include APL-2 and APL-1, to treat paroxysmal nocturnal hemoglobinuria, geographic atrophy, intermediate age-related macular degeneration, and chronic obstructive pulmonary disease. It currently has negative earnings. The firm develops APL-2 for subcutaneous injection, which is an injection into the tissue under the skin, and for intravitreal injection that is an injection into the eye, as well as APL-1 for inhaled administration.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.